CompletedPhase 2

The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans

Brazil15 participantsStarted 2007-06

Plain-language summary

The proposal of this study was to evaluate in human beings, using distortion product otoacoustic emission (DPOAE) test, the action of ginkgo biloba extract (GBE761)as a possible ear protective against cisplatin (CDDP) induced hearing loss.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Over the age of eighteen * Patients that will begin treatment with cisplatin * No prior treatment with cisplatin Exclusion Criteria: * Individuals with middle ear, cochlear or retrocochlear disease * Presence of changes in pure tone audiometry and/or distortion-product otoacoustic emissions

What they're measuring

the effect of GBE761 as a possible protector against cisplatin (CDDP) induced hearing loss was evaluated through the DPOAE. Comparisons were made between baseline measurements and those records after maximum cumulative CDDP dosage.

Timeframe: the patients were followed about ninety days

Trial details

NCT IDNCT01139281

SponsorUniversity of Brasilia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-06

View on ClinicalTrials.gov More Ototoxicity trials